Aridis Pharmaceuticals (ARDS) Competitors $0.0002 0.00 (0.00%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsSEC FilingsTrends ARDS vs. CALA, SCPS, STAB, CMRA, GNCA, GNCAQ, EVLO, AMPE, EFTR, and ONCSQShould you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Calithera Biosciences (CALA), Scopus BioPharma (SCPS), Statera Biopharma (STAB), Comera Life Sciences (CMRA), Genocea Biosciences (GNCA), Genocea Biosciences (GNCAQ), Evelo Biosciences (EVLO), Ampio Pharmaceuticals (AMPE), eFFECTOR Therapeutics (EFTR), and OncoSec Medical (ONCSQ). These companies are all part of the "pharmaceutical products" industry. Aridis Pharmaceuticals vs. Calithera Biosciences Scopus BioPharma Statera Biopharma Comera Life Sciences Genocea Biosciences Genocea Biosciences Evelo Biosciences Ampio Pharmaceuticals eFFECTOR Therapeutics OncoSec Medical Calithera Biosciences (NASDAQ:CALA) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership, community ranking and earnings. Which has stronger earnings and valuation, CALA or ARDS? Aridis Pharmaceuticals has lower revenue, but higher earnings than Calithera Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalithera Biosciences$9.75M0.00-$39.65MN/AN/AAridis Pharmaceuticals$3.09M0.00-$30.37M-$0.160.00 Does the MarketBeat Community prefer CALA or ARDS? Calithera Biosciences received 219 more outperform votes than Aridis Pharmaceuticals when rated by MarketBeat users. However, 61.00% of users gave Aridis Pharmaceuticals an outperform vote while only 57.41% of users gave Calithera Biosciences an outperform vote. CompanyUnderperformOutperformCalithera BiosciencesOutperform Votes34157.41% Underperform Votes25342.59% Aridis PharmaceuticalsOutperform Votes12261.00% Underperform Votes7839.00% Does the media refer more to CALA or ARDS? In the previous week, Calithera Biosciences had 1 more articles in the media than Aridis Pharmaceuticals. MarketBeat recorded 1 mentions for Calithera Biosciences and 0 mentions for Aridis Pharmaceuticals. Calithera Biosciences' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score. Company Overall Sentiment Calithera Biosciences Neutral Aridis Pharmaceuticals Neutral Is CALA or ARDS more profitable? Company Net Margins Return on Equity Return on Assets Calithera BiosciencesN/A N/A N/A Aridis Pharmaceuticals N/A N/A N/A Do analysts rate CALA or ARDS? Aridis Pharmaceuticals has a consensus target price of $2.00, suggesting a potential upside of 999,900.00%. Given Aridis Pharmaceuticals' higher probable upside, analysts plainly believe Aridis Pharmaceuticals is more favorable than Calithera Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calithera Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AAridis Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in CALA or ARDS? 9.7% of Aridis Pharmaceuticals shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk and volatility, CALA or ARDS? Calithera Biosciences has a beta of -1.12, suggesting that its stock price is 212% less volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. SummaryAridis Pharmaceuticals beats Calithera Biosciences on 6 of the 11 factors compared between the two stocks. Ad Paradigm PressEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart ARDS vs. The Competition Export to ExcelMetricAridis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11,000.00$6.74B$5.01B$8.40BDividend YieldN/A7.94%7.52%4.16%P/E Ratio0.0011.81128.8716.66Price / Sales0.00269.971,718.3776.45Price / CashN/A46.0936.9133.53Price / Book0.005.304.595.18Net Income-$30.37M$150.82M$114.09M$223.67M7 Day PerformanceN/A-1.00%110.31%2.58%1 Month PerformanceN/A15.26%124.28%8.66%1 Year PerformanceN/A36.69%154.64%28.23% Aridis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDSAridis Pharmaceuticals0.8992 of 5 stars$0.00flat$2.00+999,900.0%-99.8%$11,000.00$3.09M0.0030Gap UpCALACalithera BiosciencesN/A$0.01flatN/A-76.7%$29,000.00$9.75M0.0060News CoverageSCPSScopus BioPharmaN/A$0.00flatN/AN/A$21,000.00N/A0.009STABStatera BiopharmaN/A$0.00flatN/A-97.0%$11,000.00$1.49M0.0020Gap DownCMRAComera Life SciencesN/A$0.00flatN/AN/A$6,000.00$1.00M0.002GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastGNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.64M0.0070EVLOEvelo BiosciencesN/A$0.00flatN/A-99.9%$4,000.00N/A0.00120AMPEAmpio PharmaceuticalsN/A$0.00flatN/A-99.9%$2,000.00N/A0.0020EFTReFFECTOR TherapeuticsN/A$0.00flat$24.00+5,999,900.0%-100.0%$2,000.00$3.55M0.0010ONCSQOncoSec MedicalN/AN/AN/AN/A$1,000.00N/A0.0040Gap Up Related Companies and Tools Related Companies CALA Alternatives SCPS Alternatives STAB Alternatives CMRA Alternatives GNCA Alternatives GNCAQ Alternatives EVLO Alternatives AMPE Alternatives EFTR Alternatives ONCSQ Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARDS) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aridis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
